Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for bulimia nervosa with or without probable ADHD
2017-001490-16Phase 2Active
- Sponsor
- Region Stockholm
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lisdexamfetamine in bulimia nervosa (BN) (2 arms), sponsored by Region Stockholm. Primary endpoint: Difference in average weekly binge eating days between internet treatment and lisdexamfetamine treatment. Started Sep 2017; status: active.
02
Drugs
lisdexamfetamine
03
Conditions
bulimia nervosa (BN)
Beyond the preview
Go deeper on 2017-001490-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001490-16.